UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 

 

Date of Report (Date of earliest event reported): May 19, 2021

 

GLOBAL WHOLEHEALTH PARTNERS CORPORATION

(Exact name of registrant as specified in its charter)

 

 

Nevada 000-56035 46-2316220
(State or other jurisdiction
of incorporation) 		(Commission File Number) (IRS Employer
Identification No.)

 

2227 Avenida Oliva

San Clemente, CA

92673
(Address of Principal Executive Offices) (Zip Code)

 

Registrant's telephone number, including area code (714) 392-9752

N/A
(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

1 
 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Section 1 - Registrant’s Business and Operations 

Item 1.01 Entry into a Material Definitive Agreement.

 

On May 19, 2021, Global Wholehealth Partners Corporation (the “Company”) entered into an agreement (“Partnership Joint Venture Philippines Agreement”) with AAJ Partners Corp. (“AAJPC”) to form a joint venture entity Global WholeHealth Philippines (“GWP”) through which the Company and AAJPC will build a manufacturing facility in the Philippines. The Company will supply all of the tests in sheet format made under FDA GMP facility in the United States to GWP and assist GWP with FDA GMP approved facility in the Philippines. The parties have agreed in the Partnership Joint Venture Philippines Agreement that the Company will hold 40% ownership and AAJPC will hold 60% ownership.

 

The foregoing description of the joint venture does not purport to be completed and is qualified in its entirety by reference to the Partnership Joint Venture Philippines Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Section 9 – Financial Statement and Exhibits
Item 9.01 Financial Statements and Exhibits.

Exhibit No. Document Location
10.1 Partnership Joint Venture Philippines Agreement dated May 19, 2021 Filed Herewith

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

GLOBAL WHOLEHEALTH PARTNERS CORPORATION

(Registrant)

 

Date: May 21, 2021

By: /s/ Charles Strongo
Charles Strongo

Chief Executive Officer

 

 

 

 

 

 

2